
Please try another search
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis (NASH). The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is headquartered in Balma, France.
Name | Age | Since | Title |
---|---|---|---|
Cyrille Tupin | 49 | 2019 | CEO, GM & Director |
Christian Chavy | 75 | 2015 | Independent Director |
Olivier Martinez | 52 | 2015 | Censor |
Laura A. Coruzzi | 72 | 2015 | Independent Director |
Michael Harvey Davidson | 69 | 2015 | Chairman of Scientific Advisory Board |
Karen Noël | 51 | 2017 | Independent Director |
Emmanuel Huynh | 55 | 2019 | Chairman of the Board |
Jean-Gerard Galvez | - | 2024 | Director |
Luc Demarre | - | 2024 | Director |
Caroline DeSurmont | - | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review